Bruker Corporation (BRKR) Business Profile

What it does

Bruker develops, manufactures and distributes scientific instruments and analytical and diagnostic products. Its tools help customers examine biological and industrial samples at microscopic, molecular and cellular levels. Researchers use them to study the structure and function of molecules, while other customers use them for tasks such as identifying microbes, testing materials and controlling manufacturing processes.

The company’s technologies include magnetic resonance, mass spectrometry, chromatography, X-rays, microscopy and molecular spectroscopy. For example, its magnetic resonance instruments help researchers study molecular structure, while its mass spectrometers help identify and measure molecules. Bruker also supplies imaging and laboratory automation equipment, software, test kits and services.

Its customers include universities and government laboratories, pharmaceutical and biotechnology companies, hospitals, semiconductor manufacturers and other industrial businesses. Some diagnostic products are designed for clinical use in countries where the necessary regulatory approvals have been obtained; others are intended for research.

Bruker also makes superconducting materials used in applications including medical imaging and fusion energy research. Its headquarters are in Billerica, Massachusetts, and Frank Laukien is president and chief executive officer. The company maintains technical and manufacturing centers and sales offices internationally.

How it makes money

Bruker earns revenue from instruments and related products, as well as consumables, software and services. Its instruments can be part of a wider laboratory workflow: a mass spectrometer, for example, can be used with sample preparation equipment, chromatography and analysis software. Customers can also purchase reagent kits and other disposable products for tests.

In fiscal 2025, Bruker had four reportable segments. BSI BioSpin sold magnetic resonance and preclinical imaging systems, laboratory automation and lifecycle support. BSI CALID supplied mass spectrometry, molecular spectroscopy and microbiology and infection diagnostics products. BSI NANO supplied X-ray instruments, microscopy, semiconductor metrology and spatial and single-cell biology tools. BEST supplied superconducting materials and research instruments.

Bruker subsequently reorganized its scientific instruments operations. Its Biosystems group brings together businesses including magnetic resonance, mass spectrometry and optics, while microbiology and infection diagnostics operates as a separate group. Bruker Nano and BEST also remain part of the business.

Bruker estimates that about 60% of revenue comes from instruments and 40% from consumables and services. Instruments tend to have a backlog, while consumables and services have limited backlog. BioSpin offers aftermarket support, and diagnostic and cell-analysis platforms use consumable products. Bruker historically records higher revenue in the fourth quarter and lower revenue in the first, influenced by customer budgeting cycles.

Reported revenue was $874 million in the third quarter of 2026, up 1.6% year over year.

Customers and how it sells

Bruker sells to academic and government research facilities, pharmaceutical and biotechnology companies, hospitals and diagnostic laboratories. Its industrial customers include semiconductor companies, raw-material manufacturers and businesses involved in food safety, environmental testing and materials analysis. The majority of BioSpin’s customers are academic and government research facilities.

No single customer accounted for more than 10.0% of revenue in fiscal 2025. Customers also include organizations that use superconductors in medical imaging and institutions working in fusion energy and high-energy physics research.

Bruker has sales offices throughout the world and major technical and manufacturing centers in Europe and North America. Revenue from non-U.S. operations represented approximately 74% of consolidated revenue in fiscal 2025. Its operations also include research and development and manufacturing centers in Asia.

In the third quarter of 2026, European revenue rose by a low single-digit percentage on an organic year-over-year basis, Americas revenue was roughly flat and Asia-Pacific revenue declined by a mid-single-digit percentage. Within its scientific instruments business, China revenue rose by a low double-digit percentage. Bruker also sells through distributors and other third parties.

Suppliers and costs

Bruker typically manufactures critical components in-house and outsources non-critical components. Some facilities perform machining, fabrication, assembly and final testing; others focus on system integration and final testing. The company buys standard materials and components as well as items built to its specifications.

Some components come from a limited group of suppliers or a single source, including ceramics, certain detectors, X-ray tubes, robotics and infrared optics. BEST has a collaboration and joint technology development agreement with Allegheny Technologies Incorporated for niobium-based superconductors used in applications including MRI magnets.

Bruker’s costs include materials, components, manufacturing, logistics, research and development, sales and administration. In fiscal 2025, higher U.S. tariffs and foreign exchange headwinds contributed to a decline in gross profit and gross margin. Supply-chain issues and production delays have also caused additional costs and manufacturing inefficiencies.

For the third quarter of 2026, Bruker reported a 51.3% non-GAAP gross margin and a 16.3% non-GAAP operating margin. It attributed the operating margin improvement in part to cost-saving actions and product mix.

Competitive position

Bruker competes across scientific instruments, analytical tools, diagnostics, automation and materials markets. Competitors can use technologies different from Bruker’s to address the same customer needs. The company identifies application expertise, product specifications, functionality, reliability, distribution, patents and cost effectiveness as competitive factors. No specific competitors are identified here.

Some competitors have greater financial, technical and marketing resources, and some have more experience in life sciences, chemicals and materials. Bruker’s products can also be challenged by new technologies or different approaches to analysis.

Our reading: Bruker’s range of instrument technologies and application expertise can help it address specialized research and industrial workflows, but the evidence does not establish how durable that advantage is across its markets. Its combination of instruments, software, consumables and support can also help it serve customers beyond an initial equipment sale; the available evidence does not establish customer switching costs or market share.

Our reading: Patents are a potential source of protection, but their strength is uncertain because technologies can become obsolete and intellectual property protection can be challenged. Larger competitors’ resources and alternative technologies limit the evidence for a broad competitive advantage.

Growth opportunities

Bruker is developing products and workflows for proteomics, spatial biology, drug discovery, infection diagnostics and semiconductor manufacturing. In 2025, it introduced mass spectrometry technologies for proteomics and multiomics, alongside spectroscopy and dairy-testing products. It also acquired businesses providing clinical diagnostic kits and antimicrobial susceptibility testing.

In 2026, Bruker acquired a majority interest in Mimetas, which provides human organ-on-a-chip models. The company expects the business to complement its existing biology tools in drug discovery and development. Bruker also began a collaboration with and made a minority investment in Attenari Technologies, whose workflows integrate Bruker analytical instruments and ChemSpeed laboratory automation.

Scientific instruments organic bookings in China were up over 20% in both the third quarter and year to date in 2026. U.S. academic and government organic bookings grew by a double-digit percentage year over year in the third quarter, against a weak comparison. Bruker expects semiconductor metrology orders to convert into revenue in later years.

BEST received about $80 million of multi-year fusion-related research instrument orders in the first quarter of 2026 and about $600 million of multi-year superconductor orders from major MRI customers in the five months from December through April. Orders are not the same as recognized revenue.

Structural risks

• Research funding and order timing. Reduced life and materials science research spending or changes in government funding could reduce sales. Delays in Chinese government stimulus spending have already had a material adverse effect on Bruker’s business. Customers also need time to prepare sites for instruments, affecting shipment timing.
• Supply and manufacturing. Limited-source components, shortages, production delays and facility disruptions can increase costs or interrupt manufacturing. Bruker has cited challenges involving electronic components.
• Trade and currency. International sales expose Bruker to exchange-rate movements, tariffs, export controls and changing regulations. Tariff increases adopted in 2025 contributed to lower-than-anticipated bookings and revenue and reduced margins.
• Technology and competition. Products face rapid technological change and competition from alternative approaches. Inability to protect intellectual property could impair Bruker’s ability to compete.
• Regulation. Some products require medical-device clearances or other authorizations. Delays or failure to obtain them for significant products or modifications could adversely affect results; ongoing manufacturing and reporting obligations also apply.
• Debt and impairment. Debt may restrict investment opportunities or activities. In the third quarter of 2026, Bruker recorded an approximately $175 million non-cash goodwill impairment related to Spatial Biology amid weak U.S. academic and government research conditions.

Bottom line

Our reading

Our reading: Bruker combines specialized instrument sales with consumables, services and software, while its superconductors business serves a different set of industrial and research applications. That breadth gives it exposure to several customer markets, but research funding, large-equipment timing and international trade can affect results. Recent orders provide a potential revenue pipeline, though conversion depends on delivery timing and customer readiness.